trifluperidol

Trifluperidol is a typical antipsychotic drug of the butyrophenone chemical class, structurally related to haloperidol but considerably more potent by weight. It was discovered at Janssen Pharmaceutica in 1959. Trifluperidol acts primarily as an antagonist of dopamine D2 receptor (D2R) in the brain, which underlies its antipsychotic effects. It also exhibits high affinity for sigma receptor and selectively blocks NR1a/2B subunits of NMDA receptor, contributing to its pharmacological profile and potential neuroprotective properties[3][4][6]. The drug is used mainly for the treatment of psychoses including schizophrenia (especially positive symptoms), mania, hypomania, organic psychoses, childhood behavioral disorders, agitation in psychotic illness, and motor tics[2][4]. Trifluperidol can cause significant extrapyramidal side effects such as tardive dyskinesia and parkinsonian-like syndromes[3][4]. Emerging research has suggested possible antidepressant-like effects and potential antiviral activity against SARS-CoV-2 through inhibition of ADP-ribose phosphatase (ADRP) domain of Nsp3[6].

Brand names

Triperidol

Other names

trifluperidoltrifluperidol hydrochloride